Emcure Pharmaceuticals Ltd

- There is no mention of any current or future fundraising through debt or equity in the provided transcript. - The company has reduced its net debt from around ₹1,550 crores prior to the IPO to close to ₹850 crores post-IPO. - Gross debt has also decreased from about ₹2,000 crores to approximately ₹950 crores. - Interest costs are expected to reduce going forward due to this debt reduction. - The company focuses on organic growth, capacity expansion, and selective acquisitions but has not indicated any plans for new fundraising currently. - If any queries remain on this topic, the company invites investors to reach out via investor relations email.

- Emcure has operationalized four new manufacturing facilities recently to support growth levers over the next 2-3 years in India and international markets (Page 5). - These new capacities are expected to ramp up by year-end or early next year, potentially reducing the current 75-basis point margin drag (Page 18). - The company continues to invest significantly in R&D, spending 4-5% annually on a differentiated product portfolio to drive future growth (Page 15). - Emcure is actively pursuing inorganic growth opportunities including in-licensing arrangements (e.g., Sanofi cardiac portfolio) and acquisitions, with a focus on ensuring any acquisition is EPS accretive by the second year (Pages 14-15). - Focus on expanding field force, with addition of 1,200 MRs in last 18 months, supporting distribution and market penetration (Page 5). - The company is also working on filing and launching Semaglutide in India by March 2026 (Page 19).

- Emcure projects overall revenue growth of over 20% for the full year. - India business targets growing about 200 basis points higher than the industry on an organic basis. - The Canada market (including Mantra acquisition) expected to see robust growth in the short to medium term, with double-digit organic growth. - International markets, including Europe and Emerging Markets, are showing positive growth trends, with Europe expecting higher sales in later quarters. - Operational metrics such as prescription base and MR productivity are improving, with productivity expected to increase from 6.3 to around 7 by year-end. - New manufacturing capacities and field force expansion are key growth drivers. - R&D investment at 4%-5% aimed at product innovation and differentiated products will drive future sales. - Planned acquisitions and in-licensing opportunities, like Sanofi, will also contribute to growth.

- Emcure expects overall revenue growth of 20%+ for the full year FY25. - EBITDA margin is projected between 20% to 21% for the full year, with operating leverage benefits playing out. - Margin profile improvement of approximately 100 basis points is possible by year-end FY25 due to ramp up in new facilities and productivity gains. - Long-term aspiration includes achieving steady-state double-digit growth in Canada market, complemented by strong international and domestic growth. - Focus on increasing prescriptions and expanding field force to boost productivity; MR productivity expected to improve from 6.3 to about 7 by year-end. - The company aims for a 19%-20% Return on Capital Employed (ROCE) alongside 20% growth. - EPS accretive acquisitions are a focus, aiming to avoid dilution and support wealth creation. - Tax provisions remain stable with no additional provisions expected for current disputes.

- Emcure Pharmaceuticals has a healthy order book in the Emerging Markets segment. - Order book is strong in both non-ARV and ARV segments. - Non-ARV segment is witnessing traction due to differentiated products. - There is some seasonality and timing impact on Emerging Markets orders, causing quarterly volatility. - An uptick in orders from Emerging Markets is expected going forward. - The HIV/ARV business is expected to improve compared to the previous year after liquidation of COVID-induced stockpiling.